Fig. 1From: Therapeutic novelties in migraine: new drugs, new hope?Overview of patients (%) achieving 2-h pain freedom in lasmiditan phase III clinical trials with different doses. A darker bar indicates a higher dose. *vs. placebo, p < 0.001Back to article page